TechNavio's analysts forecast the Pharmerging market to grow at a CAGR of 12.44 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in healthcare spending. The Pharmerging market has also been witnessing an increase in partnerships among vendors. However, the price pressure could pose a challenge to the growth of this market.
TechNavio's report, the Pharmerging Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the pharmerging regions, namely: China, Brazil, Russia, India, Mexico, Turkey, Poland, Indonesia, Argentina, Egypt, Pakistan, South Africa, Thailand, Romania, Ukraine, Venezuela, and Vietnam; it also covers the Pharmerging market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc., Bayer HealthCare AG., Boehringer Ingelheim Pharmaceuticals Corp. Bristol-Myers Squibb Co., Eisai Co Ltd., GlaxoSmithKline plc, Johnson & Johnson, Eli Lilly and Co., Merck & Co Inc. Novartis International AG., Novo Nordisk A/S., Pfizer Inc., Roche Holding Ltd., and Sanofi S.A.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. Scope of the Report
02.1 Market Overview
03. Market Research Methodology
03.1 Market Research Process
03.2 Research Design
03.3 Research Methodology
04. List of Abbreviations
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Global Pharmaceutical Market
06.2.1 Market Size and Forecast
06.2.2 Global Pharmaceutical Market Vs Pharmerging Markets
06.3 Pharmerging Markets
06.3.1 Market Size and Forecast
06.3.2 Market Share of Pharmerging Markets vs Global Pharmaceutical Market
06.3.3 Pharmaceutical Spending in Pharmerging Markets
06.4 Five Forces Analysis
07. Market Segmentation by Geographical Regions
07.1 Pharmerging Markets Segmentation by Countries 2012-2016
07.2 SnapShot of Phamerging Markets
07.2.1 Pharmerging Markets Share by Country
08. Market Overview of Tier 1 Countries
08.1 Pharmaceutical Market in China
08.1.1 Market Size and Forecast
09. Market Overview of Tier 2 Countries
09.1 Pharmaceutical Market in Brazil
09.1.1 Market Size and Forecast
09.2 Pharmaceutical Market in Russia
09.2.1 Market Size and Forecast
09.3 Pharmaceutical Market in India
09.3.1 Market Size and Forecast
10. Tier 3 Countries
10.1 Pharmaceutical Market in Mexico
10.1.1 Market Size and Forecast
10.2 Pharmaceutical Market in Turkey
10.2.1 Market Size and Forecast
10.3 Pharmaceutical Market in Poland
10.3.1 Market Size and Forecast
10.4 Pharmaceutical Market in Indonesia
10.4.1 Market Size and Forecast
10.5 Pharmaceutical Market in Other Pharmerging Regions
10.5.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Top Pharmaceutical Companies in Pharmerging Markets
19. Key Vendor Analysis
19.1 Pfizer Inc
19.1.1 Business Overview
19.1.2 Business Segmentation
19.1.3 Key Information
19.1.4 SWOT Analysis
19.2 Novartis AG
19.2.1 Business Overview
19.2.2 Business Segmentation
19.2.3 Key Information
19.2.4 SWOT Analysis
19.3 Johnson &Johnson
19.3.1 Business Overview
19.3.2 Business Segmentation
19.3.3 Key Information
19.3.4 SWOT Analysis
19.4 Merck & Co. Inc.
19.4.1 Business Overview
19.4.2 Business Segmentation
19.4.3 Key Information
19.4.4 SWOT Analysis
19.5 GlaxoSmithKline plc
19.5.1 Business Overview
19.5.2 Business Segmentation
19.5.3 Key Information
19.5.4 SWOT Analysis
19.6 Eli Lilly and Co.
19.6.1 Business Overview
19.6.2 Business Segmentation
19.6.3 Key Information
19.6.4 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Pharmaceutical Market 2012-2016 (US $billion)
Exhibit 3: Global Pharmaceutical Market 2012 (in percent)
Exhibit 4: Pharmerging Markets 2012-2016 (US$ billion)
Exhibit 5: Pharmerging Markets Share 2012-2016 (in percent)
Exhibit 6: Pharmaceutical Spending in Pharmerging markets 2012-2016 (US$ billion)
Exhibit 7: Pharmaceutical Spending in Pharmerging Markets forecast 2012-2016 (US$ billion)
Exhibit 8: Pharmerging Markets Segmentation by Countries
Exhibit 9: Pharmerging Markets Share 2012-2016 (in percent)
Exhibit 10: Pharmerging Markets Share by Country 2012
Exhibit 11: Geographic Representation of Tier 1 Countries
Exhibit 12: Pharmaceutical Market in China 2012-2016 (US$ billion)
Exhibit 13: Geographic Representation of Tier 2 Countries
Exhibit 14: Pharmaceutical Market in Brazil 2012-2016 (US$ billion)
Exhibit 15: Pharmaceutical Market in Russia 2012-2016 (US$ billion)
Exhibit 16: Pharmaceutical Market in India 2012-2016 (US$ billion)
Exhibit 17: Geographic Representation of Tier 3 Countries
Exhibit 18: Pharmaceutical Market in Mexico 2012-2016 (US$ billion)
Exhibit 19: Pharmaceutical market in Turkey 2012-2016 (US$ billion)
Exhibit 20: Pharmaceutical Market in Poland 2012-2016 (US$ billion)
Exhibit 21: Pharmaceutical Market in Indonesia 2012-2016 (US$ billion)
Exhibit 22: Pharmaceutical Market in Other Pharmerging Regions 2012-2016 (US$ billion)
Exhibit 23: Pharmerging Markets Share Forecast in Revenue by Country 2012-2016 (US$ billion)
Exhibit 24: Pharmerging Markets Share Forecast by Country 2012-2016 (in percent)
Exhibit 25: Business Segmentation of Pfizer Inc.
Exhibit 26: Business Segmentation of Novartis AG
Exhibit 27: Business Segmentation of Johnson& Johnson
Exhibit 28: Business Segmentation of Merck& Co. Inc.
Exhibit 29: Business Segmentation of GlaxoSmithKline plc
Exhibit 30: Business Segmentation of Eli Lilly and Co.
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
